Intensive therapy with high-dose melphalan (MEL) 280 mg/m2 plus amifostine cytoprotection and ASCT as part of initial therapy in patients with multiple myeloma.

被引：0
|
作者：
Reece, DE
Vesole, D
Flomenberg, N
Badros, A
Filicko, J
Herzig, R
Howard, DS
Johnson, V
Meisenberg, B
Rapoport, A
Xun, CQ
Phillips, GL
机构：
[1] Princess Margaret Hosp, Univ Hlth Network, Toronto, ON M4X 1K9, Canada
[2] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[3] Thomas Jefferson Univ, Coll Med, Philadelphia, PA 19107 USA
[4] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
[5] Univ Kentucky, Lexington, KY 40506 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1672
引用
收藏
页码：432A / 432A
页数：1
相关论文
共 50 条
  • [1] Update of melphalan 280 mg/m2 plus amifostine cytoprotection before autologous stem cell transplantation as part of initial therapy in multiple myeloma patients.
    Reece, D. E.
    Flomenberg, N.
    Badros, A.
    Phillips, G. L.
    Filicko, J.
    Howard, D. S.
    Meisenberg, B.
    Rapoport, A.
    Vesole, D. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 448S - 448S
  • [2] Use of melphalan 280 MG/M2 plus amifostine cytoprotection and autologous stem cell transplantation in multiple myeloma patients.
    Reece, DE
    Filicko, J
    Flomenberg, N
    Howard, DS
    Meisenberg, B
    Plummer, B
    Vesole, D
    Xun, CQ
    Phillips, GL
    BLOOD, 2001, 98 (11) : 196A - 196A
  • [3] High-dose melphalan 180 mg/m2 with autologous blood stem cell transplantation for multiple myeloma.
    Dimopoulos, MA
    Papadimitriou, C
    Kostis, E
    Kouvelis, V
    Zomas, A
    Grigoraki, V
    Vervessou, E
    Sakarellou, N
    Panayiotides, P
    Anagnostopoulos, N
    BLOOD, 1999, 94 (10) : 399B - 399B
  • [4] Amifostine pretreatment for protection against Melphalan plus Busulfan-induced toxicity in high-dose therapy for multiple myeloma patients.
    Patriarca, F
    BLOOD, 1999, 94 (10) : 404B - 404B
  • [5] Intensive induction therapy with melphalan 50 mg/m2 (MEL50) for patients with AL amyloidosis
    Lee, Choon Kee
    Myint, Han
    Glen, Peterson J.
    Fred, Kolhouse J.
    Thompson, Hannis W.
    BLOOD, 2007, 110 (11) : 362B - 362B
  • [6] Dose-intensive melphalan regimens (100 mg/m2 versus 200 mg/m2) in multiple myeloma patients.
    Boccadoro, M
    Bringhen, S
    Cavallo, F
    Falco, P
    Bertola, A
    Barbui, A
    Caravita, T
    Musto, P
    Pescosta, N
    Vignetti, M
    Palumbo, A
    BLOOD, 2002, 100 (11) : 431A - 431A
  • [7] Comparison of high-dose melphalan 140 mg/m2 plus total body irradiation and high-dose melphalan 200mg/m2 as conditioning regimen for peripheral blood progenitor cell autotransplantation in patients with newly diagnosed multiple myeloma.: Preliminary results of the IFM 9502 randomized trial.
    Harousseau, JLM
    Facon, T
    Moreau, P
    Michallet, M
    Guilhot, F
    Hulin, C
    Doyen, C
    François, S
    Marit, G
    Maloisel, F
    Attal, M
    BLOOD, 1999, 94 (10) : 713A - 713A
  • [8] Total marrow irradiation (TMI) with helical tomotherapy and PBPC following high-dose melphalan and PBPC as part of tandem therapy for patients with multiple myeloma.
    Somlo, G
    Forman, S
    Poppelwell, L
    Schultheiss, T
    Frankel, P
    Krishnan, A
    Liu, A
    Sahebi, F
    Pablo, P
    Wong, J
    BLOOD, 2005, 106 (11) : 343A - 344A
  • [9] 200 mg/m2 melphalan as initial therapy in multiple myeloma:: A key to rapid achievement of complete remission.
    Powles, R
    Sirohi, B
    Singhal, S
    Goyal, S
    Treleaven, J
    Lloyd, C
    Kulkarni, S
    Mehta, J
    BLOOD, 2001, 98 (11) : 397B - 397B
  • [10] Double Transplantation with Melphalan (200 mg/m2) Compared with Triple Transplantation with Intermediate Dose Melphalan (100 mg/m2) in Patients with Multiple Myeloma
    Ludwig, Heinz
    Spicka, Ivan
    Linkesch, Werner
    Greil, Richard
    Kasparu, Hedwig
    Gunsilius, Eberhard
    Thaler, Josef
    Drach, Johannes
    Kuhn, Ingrid
    Weissmann, Adalbert
    Hinke, Axel
    BLOOD, 2008, 112 (11) : 1139 - 1139
12345